Our review provides context to clinicians regarding the use of GLP1-RA drugs in patients with or at risk of DKD to reduce UACR and help prevent adverse renal outcomes or the precipitation of ESRD in patients with T2 DM. The gene discussed is GCG; the disease is diabetic kidney disease.